Answers are grounded in this paper and cite their sources.
This experimental study demonstrates enhanced immunomodulatory effects and SARS-CoV-2 protease inhibition in nanoparticles, highlighting potential therapeutic applications.
The study explores the formulation of nanoparticles containing Begonia medicinalis extract using a blend of PLGA (Poly-Lactic-co-Glycolic Acid), sodium alginate, and polyvinyl alcohol. This formulation aimed to investigate its physicochemical properties and potential immunomodulatory and anti-SARS-CoV-2 activities. Immunomodulation was evaluated through phagocytosis activity measurement, TNF-α, and IFN-γ levels, while anti-SARS-CoV-2 activity was assessed through in vitro testing on the SARS-CoV-2 protease enzyme. Nanoparticles were prepared via the solvent evaporation method with various PLGA:alginate:PVA ratios (1:3:3, 1:3:6, 1:6:3, and 1:6:6). Characterization included organoleptic examination, particle size measurement (179.3-250.7 nm), thermal degradation at 190°C, and analysis of phytochemical content (phenolic, flavonoid, and saponin total) ranging from 18.66-21.028 mg GAE/g, 1.862-2.492 mg QE/g, and 191.975-307.897 mg EE/g, respectively. The formulations exhibited notable immune-stimulating effects by increasing phagocytotic percentage and TNF-α/IFN-γ levels and demonstrated inhibitory activity against SARS-CoV-2 3Cl protease enzyme. The encapsulation efficiency (EE) for phenolic, flavonoid, and saponin fell within the ranges of 17-19%, 16-22%, and 60-96%, respectively. Among the formulations, nanoparticle 3 (1:6:3) emerged as the optimal choice due to its superior physicochemical attributes. This particular nanoparticle exhibited immune-stimulating properties and inhibited the SARS-CoV-2 virus, suggesting its potential application in SARS-CoV-2 treatment. In conclusion, nanoparticle formulation 3 (1:6:3) displayed promising characteristics, showcasing immunomodulatory effects and anti-SARS-CoV-2 activity. This research paves the way for potential therapeutic interventions against SARS-CoV-2 using nanoparticle-based B. medicinalis extract formulations.
No takes yet. Share an insight, caveat, or question.
Zubair et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: